Results point to Enspryng® (Satralizumab) as effective in blocking IL-6 receptor and MOGAD-related inflammation.
WASHINGTON, DC, UNITED STATES, April 21, 2026 /EINPresswire.com/ -- The MOG Project is thrilled to share its excitement on the positive results Hoffmann La-Roche and Genentech announced today regarding a 44-month randomized double-blind placebo-controlled study on MOGAD. The findings were








